Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics

被引:71
作者
Johnson, AD [1 ]
Wang, DX [1 ]
Sadee, W [1 ]
机构
[1] Ohio State Univ, Integrated Biomed Sci Grad Program, Program Pharmacogenom, Dept Pharmacol,Coll Med & Publ Hlth, Columbus, OH 43210 USA
关键词
cis-regulatory; polymorphism; pharmacogenetics; pharmacogenomics; SNP; RNA; allele-specific; genotype-phenotype; cytochrome; review;
D O I
10.1016/j.pharmthera.2004.11.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional polymorphisms that alter gene expression and mRNA processing appear to play a critical role in shaping human phenotypic variability. Intensive studies on polymorphisms affecting drug response have revealed multiple modes of altered gene function, frequently involving cis-acting regulatory sequence variants. Experimental and in silico methods have advanced the search for such polymorphisms, but considerable challenges remain. Here, a survey of polymorphisms in drug-related genes indicates that: (a) a substantial proportion of genetic variability still remains unaccounted for; (b) a majority of these genes harbors known regulatory polymorphisms; and (c) a portion of polymorphisms affect splicing and mRNA turnover. Pharmacogenetic optimiziation of individual drug therapy may require a complete understanding of all functional sequence variants in key genes. This review surveys known noncoding polymorphisms in genes encoding cytochrome P450s and other drug-metabolizing enzymes, drug transporters, and drug targets and receptors. Current methods and challenges associated with the identification and characterization of functional polyrnorphisms are also discussed. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:19 / 38
页数:20
相关论文
共 254 条
[1]   DNAzymes:: From creation in vitro to application in vivo [J].
Achenbach, JC ;
Chiuman, W ;
Cruz, RPG ;
Li, Y .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (04) :321-336
[2]   Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics [J].
Adjei, AA ;
Thomae, BA ;
Prondzinski, JL ;
Eckloff, BW ;
Wieben, ED ;
Weinshilboum, RM .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (08) :1373-1382
[3]  
AENZ HM, 2004, NOVEL HIGH THROUGHPU
[4]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[5]   Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors [J].
Akiyama, TE ;
Gonzalez, FJ .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2003, 1619 (03) :223-234
[6]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[7]   Identification of a novel splice-site mutation in the CYP1A2 gene [J].
Allorge, D ;
Chevalier, D ;
Lo-Guidice, JM ;
Cauffiez, C ;
Suard, F ;
Baumann, P ;
Eap, CB ;
Broly, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :341-344
[8]   Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity [J].
Alves, S ;
Amorim, A ;
Ferreira, F ;
Prata, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :165-174
[9]   Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].
Amirimani, B ;
Ning, B ;
Deitz, AC ;
Weber, BL ;
Kadlubar, FF ;
Rebbeck, TR .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305
[10]   Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response [J].
Arranz, MJ ;
Munro, J ;
Sham, P ;
Kirov, G ;
Murray, RM ;
Collier, DA ;
Kerwin, RS .
SCHIZOPHRENIA RESEARCH, 1998, 32 (02) :93-99